Stocks opened cautiously higher to start the week, but were mixed by the close.
Monday's choppy trading likely foreshadows what we'll see throughout the week as Wall Street awaits rate-cut clues from Wednesday's release of the minutes from the July Fed meeting and Federal Reserve Chair Jerome Powell's speech this Friday at the Jackson Hole Economic Symposium.
Just days after the central bank concluded its most recent policy meeting – where it left the federal funds rate unchanged – the July jobs report came in much lower than expected.
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
The weak data immediately boosted expectations for a quarter-point rate cut at the next Fed meeting in September – and had some folks calling for a half-point reduction.
And while last week's mixed inflation data slightly lowered the odds, CME FedWatch shows futures traders are still pricing in an 83% chance the Fed will come through with a 25-basis-point cut.
"The main event for this week may very well shape expectations for the central bank's path going forward," says José Torres, senior economist at Interactive Brokers.
While a few market participants are anticipating up to three rate cuts by year's end, Torres notes that "there are some signs that inflationary pressures," and this could lead to the Fed maintaining its wait-and-see approach.
This, he adds, "certainly has the potential to disappoint Wall Street during a historically weak seasonal period."
Retail earnings roll in
It's not all about the Fed this week. Major retailers will report earnings, giving us a closer look at consumer spending amid higher tariffs and sticky inflation.
Among the most notable prints will come from Walmart (WMT, +0.7%), with the world's largest retailer set to disclose its fiscal second-quarter results ahead of Thursday's open.
UBS Global Research analyst Michael Lasser expects Walmart's earnings report to show the retailer's "underlying momentum remains strong" and that it "is in good position to generate its algorithm over a multi-year period."
Lasser has a Buy rating on the top-rated Dow Jones stock and says its current valuation – WMT is trading at 38.5 times forward earnings – is justified given its "unique opportunity for significant margin expansion" and the "consistency and visibility of its business."
Home Depot (HD), Lowe's (LOW) and BJ's Wholesale (BJ) are also some of the highlights on this week's earnings calendar.
Target gets downgraded ahead of earnings
In addition, Target (TGT, +1.9%) will report earnings this week, with the retailer's second-quarter report due out ahead of Wednesday's open.
Wall Street expects the print to show year-over-year declines on both the top and bottom lines. And BofA Securities analyst Robert Ohmes believes the company's "long-term outlook is deteriorating."
The analyst downgraded Target to Underperform from Neutral ahead of earnings, the equivalent of Sell and Hold, respectively. He also lowered his price target to $93 from $105, representing implied downside of more than 11% from today's close.
"We see increasing longer-term sales and margin risks for TGT given slowing digital sales growth, a lack of scale in digital advertising and third-party marketplace, elevated tariff, pricing and merchandising headwinds," Ohmes wrote in a note to clients.
He also noted "increasing competitive threats" from Walmart and Amazon.com (AMZN).
Most of Wall Street remains on the sidelines when it comes to Target. Of the 37 analysts covering the consumer staples stock who are tracked by S&P Global Market Intelligence, seven say it's a Strong Buy, three have it at Buy, 23 call it a Hold, and four rate it a Sell.
This works out to a consensus Hold recommendation.
Novo Nordisk gains on Wegovy's FDA win
In non-earnings news, shares of Novo Nordisk (NVO) jumped 3.7% after the company's obesity drug, Wegovy, was granted accelerated approval from the Food and Drug Administration (FDA) to treat adults with metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
This approval "could start to help shift the momentum for Novo following a more difficult start to the year for the name as competition from compounders and a series of guidance cuts weighed on shares," says BMO Capital Markets analyst Evan David Seigerman.
The analyst has a Market Perform (Hold) rating on NVO, saying he continues to view the health care stock "as a show-me story into the back half of the year."
As for the main indexes, the blue-chip Dow Jones Industrial Average slipped 0.08% to 44,911, the broader S&P 500 finished fractionally lower at 6,449, and the tech-heavy Nasdaq Composite edged 0.03% higher to 21,629.
Related content
- 12 Stocks Warren Buffett Is Buying (and Six He's Selling)
- Is Crypto Investing Coming to a Credit Union Near You?
- Mutual Funds Are About to Get the ETF Treatment. Here's What It Means for Investors
-
How Fast Does Your Internet Really Need to Be?From solo streamers to bustling smart homes, here’s how to match your internet speed to your lifestyle and know when it’s time to upgrade.
-
RMD, Roth, and SS: Test Your Knowledge of Retirement Tax RulesQuiz Don't let the IRS catch you off guard. Take our quiz to reveal common retirement tax rules that could save (or cost) you thousands.
-
I Bought Palantir When It Was Trading at $8. Now It's $180 and I've Made $1 Million. What Do I Do?What do you do with all that appreciated Palantir stock? We asked a financial expert for advice.
-
Treat Home Equity Like Other Investments in Your Retirement Plan: Look at Its Track RecordHomeowners who are considering using home equity in their retirement plan can analyze it like they do their other investments. Here's how.
-
Why Does It Take Insurers So Darn Long to Pay Claims? An Insurance Expert ExplainsThe process of verification, investigation and cost assessment after a loss is complex and goes beyond simply cutting a check.
-
Two Reasons to Consider Deferred Compensation in the Wake of the OBBB, From a Financial PlannerDeferred compensation plans let you potentially lower your current taxes and help to keep you out of a higher tax bracket. It's important to consider the risks.
-
Dow Sinks 301 Points on Trade War Talk: Stock Market TodayThe contentious relationship between the world's two biggest economies continues to drive global financial markets.
-
The Best Gold Mutual Funds to Buy Right Now — And When to Choose An ETF InsteadGold mutual funds offer investors exposure to the yellow precious metal, which has been red-hot this year. But a caveat is required.
-
Financial Fact vs Fiction: The Truth About Social Security Entitlement (and Reverse Mortgages' Bad Rap)Despite the 'entitlement' moniker, Social Security and Medicare are both benefits that workers earn. And reverse mortgages can be a strategic tool for certain people. Plus, we're setting the record straight on three other myths.
-
The End of 2%? An Investment Adviser's Case for Why the Fed Should Raise Its Inflation TargetYes, inflation can be tough on those living on fixed incomes, but protecting us from it too strictly could do our overall economy more harm than good.
